Dr Lal PathLabs

October 01, 2019

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex
Bandra (E)
Mumbai – 400 051.

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Subject: Intimation under Regulation 30(2) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Please take note that the Board of Directors of Company's Wholly Owned Subsidiary *viz.* PathLabs Unifiers Private Limited, in their meeting on October 01, 2019, approved signing a binding term sheet for acquisition of 70% equity stake in a "New Company to be incorporated".

According to the Term Sheet, the "New Company to be incorporated" will house the business of M/s Amins Pathology Referral Laboratory, a Proprietorship concern of Dr. Ripal Padmani and engaged in Pathology Business in Vadodara, Gujarat, before PathLabs Unifiers Private Limited buys 70% stake in it.

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 are provided in the **Annexure I** attached to this letter.

We request you to kindly take the same on record.

Thanking You,

Yours faithfully,
For **Dr. Lal PathLabs Limited**

Dr. Lal PathLabs Limited

Rajat Kalra
Company Secretary & Legal Head
Encl.: As above

Annexure I

Sr. No.	Particulars in respect of the Event	Details/ Information of the Event
1.	Name of the target entity, details in brief such as size, turnover etc.	**Name**: New Company to be incorporated which will house the business of M/s Amins Pathology Referral Laboratory. **Turnover**: As detailed in Point No. 10
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";	No, the transaction is not a related party transaction.
3.	Industry to which the entity being acquired belongs.	Healthcare/ Diagnostics
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To strengthen the Company's business presence in the State of Gujarat, India.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No government approvals required
6.	Indicative time period for completion of the acquisition	Within 3 months
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
8.	Cost of acquisition or the price at which the shares are acquired	Not exceeding INR 5.25 Crores
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	70% equity stake in a "New Company to be incorporated"
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information	"New Company to be incorporated" will be engaged in Healthcare / Diagnostic Services in the State of Gujarat, India, and adjoining areas and shall house the business of M/s Amins Pathology Referral Laboratory, a Proprietorship concern of Dr. Ripal Padmani and engaged in Pathology Business in Vadodara, Gujarat Turnover of M/s Amins Pathology Referral Laboratory is as below: FY17 - 3.19 Cr (Audited) FY18 - 4.03 Cr (Audited) FY19 - 5.00 Cr (Estimated)

Dr. Lal Pathlabs